Research progress of the efficacy and safety of 3-month depot Leuprorelin in the treatment of central precocious puberty
10.3760/cma.j.cn101070-20210915-01113
- VernacularTitle:亮丙瑞林3M剂型在中枢性性早熟治疗中的有效性及安全性研究进展
- Author:
Feng YE
1
;
Shengjuan JIN
;
Caiqi DU
;
Xiaoping LUO
Author Information
1. 华中科技大学同济医学院附属同济医院儿科，武汉 430030
- Keywords:
Central precocious puberty;
Leuprorelin;
Gonadotropin-releasing hormone analogue;
Luteinizing hormone
- From:
Chinese Journal of Applied Clinical Pediatrics
2022;37(23):1828-1832
- CountryChina
- Language:Chinese
-
Abstract:
Central precocious puberty (CPP) is a common pediatric endocrine disease caused by premature activation of the hypothalamic-pituitary-gonadal axis, featured by rapid development of internal and external reproductive organs and secondary sexual characteristics in girls before age 8 and boys before age 9.The gonadotropin-releasing hormone analogue (GnRHa) is the first choice for the treatment of CPP.Currently, 3.75 mg/ month sustained -release short-acting dosage form (1M depot formulations) is the most commonly used in China.The development of long-acting dosage form will reduce injection times and clinic visits.At present, the 3-month long-acting dosage form (11.25 mg 3M depot formulations) of Leprorelin microsphere has been approved in China.However, clinical practice experience of 3-month Leuprorelin acetate depot formulations is lacking in China.Therefore, in this paper, existing clinical evidence for this dosage form was reviewed to provide evidence-based medicine support for its clinical application.
